Combined Dacomitinib and Selpercatinib Treatment for a Patient with EGFR-Mutant Non-Small Cell Lung Cancer and Acquired CCDC6-RET Fusion
Cheng-Yin Liu,Chia-Hsin Liu
DOI: https://doi.org/10.2147/ott.s470946
IF: 4
2024-06-19
OncoTargets and Therapy
Abstract:Cheng-Yin Liu, 1, 2 Chia-Hsin Liu 1 1 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; 2 Department of Internal Medicine, Hualien Armed Forces General Hospital, Hualien City, Taiwan Correspondence: Chia-Hsin Liu, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, 325, Section 2, Cheng-Gung Road, Nei-Hu Dist. 114, Taipei, Taiwan, Tel +886-2-8792-3311 Ext 16881, Email RET rearrangements are recognized drivers in lung cancer, representing a small subset (1– 2%) of non-small cell lung cancer (NSCLC). Additionally, RET fusions also serve as a rare acquired resistance mechanism in EGFR -mutant NSCLC. Only a few NSCLC cases have been reported with co-occurrence of EGFR mutations and RET fusions as an acquired resistance mechanism induced by EGFR-tyrosine kinase inhibitors (TKIs). A 68-year-old man diagnosed with lung adenocarcinoma harboring EGFR L858R mutation initially responded well to dacomitinib, a second-generation EGFR-tyrosine kinase inhibitor (TKI). Afterward, he developed acquired resistance accompanied by a RET rearrangement. Next-generation sequencing (NGS) analysis revealed that the tumor possessed both the new CCDC6-RET fusion and the EGFR L858R mutation. Subsequently, he was treated with a combination of cisplatin, pemetrexed, and bevacizumab resulting in a partial response. Nevertheless, his condition deteriorated as the disease progressed, manifesting as hydrocephalus, accompanied by altered consciousness and lower limb weakness. The subsequent combined treatment with dacomitinib and selpercatinib resulted in a significant improvement in neurological symptoms. Here, we first identified acquired CCDC6-RET fusion with a coexisting EGFR L858R mutation following dacomitinib treatment. Our findings highlight the importance of NGS for identifying RET fusions and suggest the potential combination of dacomitinib and selpercatinib to overcome this resistance. For NSCLC patients with RET rearrangements and no access to RET inhibitors, pemetrexed-based chemotherapy provides a feasible alternative. Keywords: NSCLC, RET rearrangement, EGFR mutation, dacomitinib, selpercatinib, NGS Dacomitinib, an irreversible second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has shown superior progression-free survival (PFS) and overall survival (OS) over gefitinib in patients with advanced non-small cell lung cancer (NSCLC) in the ARCHER 1050 study. 1,2 Nevertheless, despite high initial response rates, patients typically develop acquired resistance to dacomitinib treatment after approximately 1 to 2 years. RET rearrangements are recognized drivers in lung cancer, representing a small subset (1–2%) of NSCLC, and are also identified as a rare, acquired resistance mechanism in EGFR -mutant NSCLC. 3 There have been only a few reported NSCLC cases with coexisting EGFR mutations and RET fusions induced by EGFR-TKIs. 4,5 Here, we present a case of dacomitinib-induced CCDC6-RET fusion concurrent with an EGFR L858R mutation, successfully treated through a combination of dacomitinib and selpercatinib. A 68-year-old non-smoker male presented to the emergency department with a 2-month history of non-productive cough, dyspnea on exertion, weight loss, and progressive lower limb weakness. A chest X-ray (CXR) revealed a left-sided opacity (Figure 1A), and the contrast-enhanced chest computed tomography (CT) identified a 7 x 7 cm mass in the left upper lobe with contralateral mediastinal lymph nodes enlargement, and multiple bone metastases (Figure 1B). Brain magnetic resonance imaging (MRI) showed a 2.2×1.6 x 1.5 cm lesion with mixed signal intensity in the left thalamus indicative of a metastatic lesion with associated hemorrhage (Figure 2A). Moreover, multiple nodular metastases were identified in the left cerebral hemisphere, along with a metastatic lesion in the left parietal bone. A lung tumor biopsy showed a poorly differentiated lung adenocarcinoma with EGFR Ex21 L858R mutation. The patient was diagnosed with stage IVB (T4N3M1c) lung adenocarcinoma, characterized by mediastinal lymphadenopathy and metastases to the brain and multiple bones. Figure 1 Radiographic findings before and after dacomitinib treatment. ( A ) Chest X-ray showed a mass-like opacity in the left lung field. ( B ) CT scan displayed a 7×7 cm mass in the left upper lobe, with enlarged contralateral mediastinal lym -Abstract Truncated-
oncology,biotechnology & applied microbiology